ReviewCancer reports (Hoboken, N.J.)2025
The Role of PIWI-Interacting RNA in Urologic Carcinoma and Its Clinical Implications.
Review in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of PIWI-Interacting RNA in Urologic Carcinoma and Its Clinical Implications.Cancer reports (Hoboken, N.J.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Piwi-interacting RNA (piRNA) represents a class of small non-coding RNA molecules, typically ranging in length from 18 to 35 nucleotides. These molecules are critically involved in the preservation of genomic integrity and the regulation of protein translation processes. Recently, emerging scholarly research indicates that piRNA exhibits tissue-specific expression profiles within a variety of human malignancies, where they intricately regulate key signaling pathways at both the transcriptional and post-transcriptional levels. This review systematically underscores current investigations pertaining to piRNA in urologic carcinoma (UC), elucidating the proposed regulatory mechanisms encompassing N6-methyladenosine (m6A) modification and the silencing of transposable elements. Furthermore, we discuss the detection technology and the application of piRNA in the fields of clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.